RNU6-976P

Across TCGA pan-cancer cohorts, RNU6-976P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated RNU6-976P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-976P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-976P expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

LIHC, KIRP, and MESO are the cancer types where RNU6-976P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.051	0.783	<.001	108	view →
KIRP	DFS	Tertile	All	0.519	0.920	<.001	60	view →
MESO	DFS	Tertile	III,IV	0.082	0.414	.007	36	view →
SARC	OS	Tertile	All	0.511	0.860	<.001	27	view →
OV	OS	Tertile	III,IV	0.811	0.671	.025	24	view →
SKCM	OS	Tertile	All	0.307	0.786	.025	9	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RNU6-976P–LIHC (OS)

Open the LIHC breakdown →